

Tetrahedron Letters 41 (2000) 6769-6773

TETRAHEDRON LETTERS

## Synthesis of picropodophyllin homolactone

Emmanuel Roulland,<sup>a</sup> Emmanuel Bertounesque,<sup>a,\*</sup> Christiane Huel<sup>b</sup> and Claude Monneret<sup>a,\*</sup>

<sup>a</sup>UMR 176 CNRS-Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France <sup>b</sup>U 350 INSERM-Institut Curie, Bâtiment 110, Université Paris XI, F-91405 Orsay Cedex, France

Received 24 May 2000; accepted 5 July 2000

## Abstract

Based on a Wittig olefination strategy, the first synthesis of picropodophyllin homolactone 2 is described in nine steps and 30% overall yield from podophyllotoxine 1. The relative configuration of 2 was unambiguously determined using 2D NOESY NMR and a Monte Carlo search protocol. This work corrects the literature on the synthesis of 2. © 2000 Elsevier Science Ltd. All rights reserved.

We have been engaged in activities<sup>1</sup> in the area of podophyllotoxin  $1,^2$  a natural product endowed with potent antimitotic activity. The *trans*-fused lactone moiety is being considered as an important factor for displaying significant cytotoxic activity,<sup>3</sup> the *cis* analogues being less potent. Less is known concerning six-membered ring lactone analogues. In 1985, Anjanamurthy and Lokanatha Rai<sup>4</sup> reported the synthesis of picropodophyllin homolactone **2**. However, it appeared to us that the IR absorption at 1760 cm<sup>-1</sup> was not consistent with a  $\delta$ -lactone functionality. In this communication, we describe the first synthesis of picropodophyllin homolactone **2** via a route which would accomodate a good degree of flexibility with respect to the size and nature of the D-ring.



The synthesis of picropodophyllin homolactone **2** began with podophyllotoxin **1**, which was transformed into  $3^5$  (97%) through silylation (TBSOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, 0°C) of the benzylic

<sup>\*</sup> Corresponding authors. Tel: +33-(0)1-42-34-66-55; fax: +33-(0)1-42-34-66-31; e-mail: claude.monneret@curie.fr

alcohol (Scheme 1). Subsequent hydrolysis of the  $\gamma$ -lactone (2N NaOH, THF, 0°C) afforded the resulting hydroxy-acid 4 (quantitative yield) with epimerization at the C<sub>2</sub> stereocenter. Oxidation of 4 to the low soluble lactols 5 (Dess–Martin periodinane, CH<sub>2</sub>Cl<sub>2</sub>, 25°C) followed by esterification (CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, acetone, 25°C) provided the desired aldehyde 6 (87% yield for the two steps). Similar lactol compounds have been used in the asymmetrical total synthesis of (–)-podophyllotoxin reported by Bush and Jones.<sup>6</sup> Alternatively, according to earlier observations,<sup>7</sup> transesterification of 3 under equilibrating conditions (K<sub>2</sub>CO<sub>3</sub> cat., MeOH, 25°C) resulted in a mixture of picropodophyllin derivative 7<sup>5</sup> (43%) and methyl picropodophyllate derivative 8 (57%). Usefully, the overall yield of 8 was improved to 86%, since it was possible to recycle (three cycles) the undesired lactone 7 by conversion into the methyl ester 8 using the same procedure. A Swern oxidation of the resulting alcohol also afforded the subgoal 6. The one-carbon homologation and the completion of the synthesis were then addressed (Scheme 2).



Scheme 1. (a) TBSOTf, 2,6-lutidine,  $CH_2Cl_2$ , 0°C. (b) NaOH, THF/H<sub>2</sub>O, 0°C. (c) Dess–Martin periodinane,  $CH_2Cl_2$ , 25°C. (d)  $CH_3I$ ,  $K_2CO_3$ , acetone, 25°C. (e)  $K_2CO_3$  cat., MeOH, 25°C. (f) (ClCO)<sub>2</sub>, DMSO, Et<sub>3</sub>N,  $CH_2Cl_2$ , -78 to 25°C



Scheme 2. (a) Ph<sub>3</sub>P+CH<sub>2</sub>OCH<sub>3</sub> Cl<sup>-</sup>, *n*-BuLi, THF, -40 to 25°C. (b) 30% HClO<sub>4</sub>/H<sub>2</sub>O, Et<sub>2</sub>O, 25°C. (c) NaBH<sub>4</sub>, MeOH, 25°C. (d) SiO<sub>2</sub>, MeOH, reflux

The enol ether functionality of **9** was stereoselectivity incorporated (84% overall yield, *E:Z* ratio = 60:40 by <sup>1</sup>H NMR analysis) by treating **6** with methoxymethylenetriphenylphosphonium chloride and *n*-BuLi.<sup>8</sup> A subsequent hydrolysis of **9** (30% HClO<sub>4</sub>/H<sub>2</sub>O, Et<sub>2</sub>O, 25°C) afforded an inseparable 1:5 mixture of the stable  $\gamma$ -lactols **10** (55%). This transformation accomplished not only the two deprotection operations, but also the unwanted epimerization at C<sub>4</sub>. Attempts to avoid the acidic removal of the TBS ether protecting group by the method of Yamamoto<sup>9</sup> (TBAF, BF<sub>3</sub>-Et<sub>2</sub>O) also led to **10**, but in low yield. Sequential reduction (NaBH<sub>4</sub>, MeOH, 25°C) of **10** and acidic treatment of the resultant diol gave a mixture of the anticipated<sup>10</sup>  $\gamma$ -lactone **11** (83%), encompassing a neopodophyllotoxin-like structure,<sup>11</sup> and hydroxy-ester **12** (9%). The utility of **11**<sup>12</sup> as a viable intermediate in the synthesis of **2** was not examined. Consequently, we chose to subject aldehyde **6** to a Wittig methylenation (76%) in order to suppress the problematic acidic hydrolysis of the enol ether **9** (Scheme 3).



Scheme 3. (a)  $Ph_3P^+CH_3 I^-$ , *n*-BuLi, THF, -78°C. (b) TBAF, THF, 25°C. (c) 9-BBN, THF then 30%  $H_2O_2/H_2O$ , phosphate buffer, pH 7, MeOH, 25°C. (d) NaOH, THF/H<sub>2</sub>O, 0°C. (e) DCC, 4-DMAP, THF, 25°C

Attempted direct alkene hydroboration of 13 by means of conventional reagents (9-BBN, BH<sub>3</sub>/SMe<sub>2</sub>) failed to provide the desired TBS ether analogue of 15. However, diol 15 was conveniently prepared in 56% overall yield by deprotection of the sterically hindered TBS ether and subsequent hydroboration (9-BBN, THF, 25°C) of the olefin 14. The coupling constants of 15  $(J_{1,2}=8.9, J_{2,3}=3.5 \text{ and } J_{3,4}=4.4 \text{ Hz})$  were similar to those found for methyl picropodophyllate.<sup>13</sup>

The synthesis was then completed by saponification of **15**, giving the crude  $\delta$ -hydroxy-acid, which was immediately treated with DCC and 4-DMAP to afford the desired  $\delta$ -lactone **2**<sup>14</sup> in 84% overall yield. The structure of **2** was established unambiguously on the basis of a spectroscopic analysis (<sup>1</sup>H NMR (400 MHz), 1D, 2D NOESY; <sup>13</sup>C NMR (100 MHz); IR) and molecular modeling. This product was clearly different from that described earlier<sup>4</sup> by comparison of their melting points and spectroscopic data (<sup>1</sup>H NMR, IR). The IR absorption at 1741 cm<sup>-1</sup> indicated the presence of a  $\delta$ -lactone functionality. A Monte Carlo search (SYBYL 6.5/Tripos force field) gave the lowest energy conformations as **A** and **B** respectively, for the *cis*-lactone **2** and the *trans*-isomer **16** (Fig. 1). The vicinal coupling constants (H-1, H-2, H-3, H-4) and the observed NOESY (absence of H-2/H-4 and H-3/H-12a interactions, strong H-2/H-12a NOESY) confirm structure **2** for the synthesized lactone, in good agreement with a conformation such as **A**. These data allow us to exclude structure **16**.



Compounds 10, 11 and 2 displayed low activities in vitro against L1210 (IC<sub>50</sub> values in  $\mu$ M: 10, 23.5; 11, 21; 2, 1.3; 1, 0.007).

In summary, the first synthesis of 2 has been achieved from podophyllotoxin 1 in nine steps and 30% overall yield. Moreover, our route should allow the construction of podophyllotoxin analogues including D-rings of various sizes and degrees of substitution, from the key intermediate 6. Such an approach is currently under investigation.

## Acknowledgements

This work was financially supported by the Centre National de la Recherche Scientifique and the Institut Curie. We also thank the Laboratoires Servier, France, for biological evaluations.

## References

- 1. Bertounesque, E.; Imbert, T.; Monneret, C. *Tetrahedron* 1996, 52, 14235–14246. Daley, L.; Meresse, P.; Bertounesque, E.; Monneret, C. *Tetrahedron Lett.* 1997, 38, 2673–2676.
- Damayanthi, Y.; Lown, J. W. Curr. Med. Chem. 1998, 5, 205–252. Zhang, Y.; Lee, K.-H. Chin. Pharm. J. 1994, 46, 319–369.
- 3. Sackett, D. L. Pharmac. Ther. 1993, 59, 163-228.
- 4. Anjanamurthy, C.; Lokanatha Rai, K. M. Indian J. Chem. 1985, 24B, 502-504.
- Andrews, R. C.; Teague, S. J.; Meyers, A. I. J. Am. Chem. Soc. 1988, 110, 7854–7858. Kende, A. S.; King, M. L.; Curran, D. P. J. Org. Chem. 1981, 46, 2826–2828.
- 6. Bush, E. J.; Jones, D. W. J. Chem. Soc., Perkin Trans. 1 1996, 151-155.
- 7. Gensler, W. Y.; Gatsonis, C. D. J. Org. Chem. 1966, 31, 3224-3227.
- Wittig, G.; Schlosser, M. Chem. Ber. 1961, 94, 1373–1383. Maryanoff, B. E.; Reitz, A. B. Chem. Rev. 1989, 89, 863–927.
- 9. Gevorgyan, V.; Yamamoto, Y. Tetrahedron Lett. 1995, 36, 7765-7766.
- Brown, J. M.; Conn, A. D.; Pilcher, G.; Leitão, M. L. P.; Meng-Yan, Y. J. Chem. Soc., Chem. Commun. 1989, 1817–1819.
- Forsey, S. P.; Rajapaksa, D.; Taylor, N. J.; Rodrigo, R. J. Org. Chem. 1989, 54, 4280–4290. Renz, J.; Kuhn, M.; von Wartburg, A. Liebigs Ann. Chem. 1965, 681, 207–224. Charlton, J. L.; Koh, K. J. Org. Chem. 1992, 57, 1514– 1516.
- 12. Analytical data for compound **11**. Mp: 88–90°C; [α]<sub>D</sub><sup>25</sup> +42 (*c* 0.4; CHCl<sub>3</sub>); IR (CDCl<sub>3</sub>) 3628, 2938, 1769 cm<sup>-1</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.43 (t, 1H, *J*=4.7 Hz, OH), 1.62 (m, 1H, H-11a), 1.81 (m, 1H, H-11b), 2.78 (d, 1H,

J=1.1 Hz, H-2), 2.86 (t, 1H, J=7.3 Hz, H-3), 3.72 (m, 2H, H-12a, H-12b), 3.78 (s, 6H, OMe), 3.84 (s, 3H, OMe), 4.41 (d, 1H, J=1.1 Hz, H-1), 5.10 (d, 1H, J=1.0 Hz, H-4), 5.94 (d, 1H, J=1.2 Hz, OCH<sub>2</sub>O), 5.99 (d, 1H, J=1.2 Hz, OCH<sub>2</sub>O), 6.31 (s, 2H, H-2', H-6'), 6.49 (s, 1H, H-8), 6.75 (s, 1H, H-5); MS (DCI/NH<sub>3</sub>) m/z 429 [M+H]<sup>+</sup>, 446 [M+NH<sub>4</sub>]<sup>+</sup>.

- Gordaliza, M.; Castro, M. A.; Miguel del Corral, J. M.; López-Vázquez, M. L.; García, P. A.; San Feliciano, A.; García-Grávalos, M. D.; Broughton, H. *Tetrahedron* 1997, 53, 15743–15760.
- 14. Analytical data for compound 2. Mp: 197–198°C (hexane/EtOAc), lit.:<sup>4</sup> 144–146°C; [α]<sub>D</sub><sup>25</sup> –114 (*c* 0.1; CHCl<sub>3</sub>); IR (CDCl<sub>3</sub>) 3800–3400, 2932, 1741, 1591 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.09–2.19 (m, 2H, H-11a, H-11b), 2.43 (bs, 1H, OH), 2.53 (m, 1H, H-3), 3.01 (dd, 1H, *J* = 6.4, 2.9 Hz, H-2), 3.79 (s, 6H, OMe), 3.84 (s, 3H, OMe), 4.26–4.35 (m, 1H, H-12a), 4.38 (d, 1H, *J* = 9.6 Hz, H-4), 4.43–4.51 (m, 1H, H-12b), 4.64 (d, 1H, *J* = 2.9 Hz, H-1), 5.91–5.94 (degenerated m, 2H, OCH<sub>2</sub>O), 6.30 (s, 2H, H-2', H-6'), 6.43 (s, 1H, H-8), 7.00 (s, 1H, H-5); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) quaternary carbons not specifically assigned δ 24.9 (C-11), 34.2 (C-3), 43.6 (C-1), 46 (C-2), 56 (2C, OMe), 60.7 (1C, OMe), 66 (C-12), 71.4 (C-4), 101 (OCH<sub>2</sub>O), 105.8 (C-5), 105.9 (2C, C-2', C-6'), 109.4 (C-8), 128, 131.5, 137, 136.8 (quaternary carbons C-1', C-4', C-4a, C-8a), 146.9, 147.4 (quaternary carbons C-6, C-7), 153.2 (2C, C-3', C-5'), 173 (C=O); MS (DCI/NH<sub>3</sub>) *m/z* 446 [M+NH<sub>4</sub>]<sup>+</sup>.